Jean-Phillippe Courtois, a non-executive director at AstraZeneca, has spent nearly £50,000 upping his stake in the drug giant.
He bought 2,135 shares for 2,299p each and now has 2,635.
News of his purchase came on the same day AstraZeneca was celebrating a favourable decision from US regulators regarding its new drug application for diabetes treatment ONGLYZA.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee decided that the data supporting the drug application for ONGLYZA were sufficient to discount unacceptable cardiovascular risk.
Courtois, who is also the President of software company Microsoft's non-US operations, was appointed to Astra's board on February 18.
Top Director Buys
Value: £99,120
Value: £99,120
Value: £98,000
Value: £49,084
Value: £25,002
Value: £25,000
Value: £25,000
Value: £14,600
Value: £13,411
Value: £12,250
Top Director Sells
Value: £2,800,000
Value: £321,247
Value: £10,040
-
What happens if you can’t pay your tax bill, and what is "Time to Pay"?Millions are due to file their tax return this Friday as the self-assessment deadline closes. Though the nightmare is not over until you pay the taxman what you owe - or face a penalty. But what happens if you can't afford to pay HMRC your tax bill, and what is "Time to Pay"?
-
What does Rachel Reeves’s plan for growth mean for UK investors?Rachel Reeves says she is going “further and faster” to kickstart the UK economy, but investors are unlikely to be persuaded
